Validation

Cleerly® Announces CERTAIN Multicenter Clinical Trial Results

Retrieved on: 
Thursday, February 8, 2024
Health, Clinical Trials, Cardiology, Other Health, Drug, Ischemia, MD, American College, Derivation, Cole, Detection, Medicine, Intelligence, Artificial intelligence, Coronary ischemia, Science, Atherosclerosis, Society, CCTA, Myocardial perfusion imaging, PMID, Plaque, SPECT, PET, FDA, Adenosine, American Journal of Roentgenology, Diagnosis, Patient, Stenosis, Moyamoya disease, Validation, Splenic infarction, Physician, Health literacy, Journal, Coronary artery disease, Coronary, Medical imaging

These results underscore the strong and positive effect of the Cleerly products on clinical utility for patients with suspected coronary artery disease.

Key Points: 
  • These results underscore the strong and positive effect of the Cleerly products on clinical utility for patients with suspected coronary artery disease.
  • In all multicenter and single clinical studies performed to date, Cleerly’s products have consistently demonstrated robust clinical utility, including higher diagnostic accuracy and stronger prognostic risk stratification over such historical tests as nuclear SPECT stress testing and FFRCT2-7.
  • Cleerly’s approach is grounded in science, based on over 10 million images from over 40,000 patients gathered over a 15-year-period in landmark, multi-center clinical trials.
  • Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway.

Amogy Issued Feasibility Statement by Lloyd’s Register

Retrieved on: 
Thursday, February 8, 2024
Environment, Technology, Semiconductor, Maritime, Transport, Oil, Gas, Sustainability, Alternative Energy, Green Technology, Energy, Classification, Inc., Safety, Nitrogen, Validation, Hydrogen, TQP, Renewable energy

Amogy Inc. (“Amogy”), a pioneer of carbon-free, energy-dense ammonia power solutions, has been awarded a feasibility statement by Lloyd’s Register (“LR”), a leading provider of classification and compliance services to the maritime and offshore industries.

Key Points: 
  • Amogy Inc. (“Amogy”), a pioneer of carbon-free, energy-dense ammonia power solutions, has been awarded a feasibility statement by Lloyd’s Register (“LR”), a leading provider of classification and compliance services to the maritime and offshore industries.
  • Development and approval of the TQP is a part of the Validation phase and the feasibility statement confirms that a concept is capable of being developed into a viable technology.
  • Amogy recently completed the Technology Verification phase with LR and, upon receipt of this Statement of Feasibility, will now begin to execute the component testing as outlined in the TQP.
  • “Receiving this Statement of Feasibility from Lloyd’s Register is a major milestone in affirming the safety and viability of our ammonia-to-electrical power system,” said Seonghoon Woo, CEO of Amogy.

Zelis® Payment Integrity Named 2024 Best in KLAS, Outpacing the Industry for Client Experience, with System Integration and Achieved Client Outcomes

Retrieved on: 
Wednesday, February 7, 2024
Data Management, Practice Management, Technology, Professional Services, Managed Care, Health, General Health, Health Technology, Health Insurance, Fintech, Human Resources, Partnership, Multimedia, Software, Fraud, DRG, Nursing, Price optimization, Validation, Physician, Risk, CMS, Integrity, Health insurance

Zelis , a leading provider of healthcare technology solutions, today announced that its Payment Integrity solutions received the top honor for Payment Accuracy & Integrity Solutions (Payer) segment in the 2024 Best in KLAS Awards – Software and Services .

Key Points: 
  • Zelis , a leading provider of healthcare technology solutions, today announced that its Payment Integrity solutions received the top honor for Payment Accuracy & Integrity Solutions (Payer) segment in the 2024 Best in KLAS Awards – Software and Services .
  • The annual ranking recognizes software and services companies that excel in helping healthcare professionals improve patient care.
  • View the full release here: https://www.businesswire.com/news/home/20240207862334/en/
    This recognition follows KLAS’s inaugural report for payers, Payment Accuracy & Integrity Solutions 2023 , which identified Zelis Payment Integrity as a top overall performer based on client ratings.
  • Zelis received an overall performance score of 93.9 out of 100, outpacing the seven other companies surveyed in the payment integrity space.

Ispire Technology Inc. Announces Opening of New ISO- and GMP-Certified Malaysia Manufacturing Facility

Retrieved on: 
Monday, February 5, 2024
LOS, Cannabis, Cleanroom, Nicotine, Standard operating procedure, Quality management system, Validation, Environmental management system, Risk management, QMS, Environmental monitoring, Material Control, Wang, ISPR, GMP, Traceability, Quality control, Battery

LOS ANGELES, Feb. 5, 2024 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ: ISPR), a leader in the development and commercialization of vaping technology and precision dosing, announced the opening of its new ISO- and GMP-certified 31,000 sq. ft. manufacturing facility in Malaysia, which is poised to help expedite market entry for businesses seeking to enhance their cannabis and nicotine product lines.

Key Points: 
  • ft. manufacturing facility in Malaysia, which is poised to help expedite market entry for businesses seeking to enhance their cannabis and nicotine product lines.
  • Located in Senai, Ispire's facility recently secured certifications including: ISO9001:2015 Quality Management System; ISO14001:2015 Environmental Management System; and ISO13485:2016 Quality Management System Medical Device.
  • "The inauguration of our ISO- and GMP-certified vapor device facility in Malaysia marks a significant milestone in our Company's journey," said Ispire Technology Co-Chief Executive Officer Michael Wang .
  • This facility adheres to established standards and reflects the dedication of our team in establishing a manufacturing facility that sets the worldwide industry standard for vaporized products."

AnaCredit Validation Checks – Version 1.8

Retrieved on: 
Sunday, January 28, 2024
Sale, Commitment, Logic, Record, Default, Central bank, Date, MFI, AnaCredit, Validation, Probability, Instrument, Inception, Encumbrance, Collection, Part Two, DOES, NCB, Element, Section 4, T-3, NOT, Accounting, Creditor, Language, ECB, Fahd of Saudi Arabia, Classification, LEI, Completeness, Table, NCBS, Definition, FVC, European Central Bank, Protection, Ultimate, Section, Data collection, ID, Data, Data set, Commission, Interest, Communication, Next, Prudential, GAAP, OJ, Head, Boilermaker
Key Points: 

<ul></ul>

Revolutionizing Hemorrhoid Relief: Introducing HemFuse EXT with Aquamin™

Retrieved on: 
Wednesday, January 10, 2024
Inflammation, Hemorrhoid, Safety, Health, Validation, Pain, Pharmaceutical industry

ROSEVILLE, Calif., Jan. 10, 2024 /PRNewswire-PRWeb/ -- Exclusive Pharmaceuticals, a trailblazer in health and wellness solutions, is proud to announce the launch of HemFuse EXT, a groundbreaking patented capsule formula designed to bring unprecedented relief to individuals suffering from hemorrhoids. This innovative product features the incorporation of Aquamin™, a key ingredient known for its natural healing properties, setting a new standard in the field of hemorrhoid relief.

Key Points: 
  • Patented Capsule Formula: HemFuse EXT stands out as a result of its proprietary formula, combining a patented blend of ingredients with the healing power of Aquamin™.
  • Extended Relief: The capsule form of HemFuse EXT allows for extended relief, providing a sustained release of the active ingredients.
  • Convenient and Discreet: The capsule format of HemFuse EXT offers users a convenient and discreet option for managing hemorrhoid symptoms.
  • For more information on HemFuse EXT with Aquamin™, please visit https://exnutrition.com/ or contact Branden, Founder, at [email protected] .

Pan American Energy Corp Announces One of the Largest Identified Lithium Deposits in the US at the Horizon Lithium Project

Retrieved on: 
Monday, November 20, 2023
Diamond, Lithium, QP, Marketing, Siebert, Mineral Resources Limited, Classification, LCE, Resource, Validation, Acquisition, Pan-American, Mining, QA/QC, MRE, ID2, ICP-MS, Risk, 3D, Engineering, Internal, Project, Mineral, ALS, Uranium mining

In order to describe the resource in terms of ‘industry standard’ lithium carbonate equivalent, a conversion factor of 5.323 was used to convert elemental lithium to LCE.

Key Points: 
  • In order to describe the resource in terms of ‘industry standard’ lithium carbonate equivalent, a conversion factor of 5.323 was used to convert elemental lithium to LCE.
  • The estimate of Mineral Resources may be materially affected by environmental, permitting, legal, title, taxation, socio-political, marketing or other relevant issues.
  • All figures are rounded to reflect the relative accuracy of the estimate and numbers may not add due to rounding.
  • The MRE was estimated from the diamond drill holes completed by Pan American since ‎February 2023.

Validation Institute Announces First Group of Speakers for Food as Medicine Strategy Summit, May 29-31, 2024, in Washington, D.C.

Retrieved on: 
Wednesday, December 20, 2023
Faculty, Food, Nutrition, Validation, JD, Health, World Food Programme, MD, Certification, Sieve, Fellow, Albertsons, USDA, Food security, Content, Summit, Former, EVP, Management

NEEDHAM, Mass., Dec. 20, 2023 /PRNewswire-PRWeb/ -- As part of its FoodMed Certified initiative, Validation Institute (VI) announced the first group of confirmed speakers for its inaugural Food as Medicine Strategy Summit, taking place May 29-31, at The Westin Washington, DC Downtown.

Key Points: 
  • FoodMed Certified, launched by Validation Institute earlier this year with support from Founding Members, Albertsons Companies, Avēsis, Mom's Meals®, Sifter, and Uber Health, is the first certification and validation initiative for food as medicine programs.
  • "FoodMed Certified's mission is to promote the use of food as medicine in the prevention and intervention of illness by validating proven solutions that enable people to better manage their health through tools and nutritious food programs.
  • "The speakers at the Food as Medicine Strategy Summit are highly accomplished and bring a diverse array of real-world perspectives on the practical application and integration of food in health and healthcare.
  • We are honored to have them on the program and look forward to making more faculty announcements in the coming weeks," Ms. Krishnarathnam continued.

Enable Biosciences Receives $3M Phase IIB SBIR Award from NIDDK for Advanced T1D Testing Technology

Retrieved on: 
Tuesday, December 19, 2023
Carolyn Bertozzi, Autoantibody, Risk, SBIR, Validation, FDA, Digestive, Disease, Kidney, SAN, Doctor of Philosophy, NIDDK, Type 1 diabetes, ADAP, Safety

A key objective of this funding is to pursue FDA clearance for the T1D test, a critical step towards commercialization.

Key Points: 
  • A key objective of this funding is to pursue FDA clearance for the T1D test, a critical step towards commercialization.
  • Dr. Jason Tsai, PhD, Chief Technical Officer at Enable Biosciences, shared his enthusiasm: "This Phase IIB SBIR award from NIDDK is a testament to our dedication to transforming T1D testing.
  • The NIDDK's support is pivotal for Enable Biosciences in its pursuit of FDA clearance for its innovative T1D test.
  • For more information about Enable Biosciences and their cutting-edge approach to T1D testing, visit www.enablebiosciences.com or contact their media team for further details and inquiries.

Sosei Heptares and Kallyope Nominate First GPCR Target for Therapeutic Development in Gastrointestinal Diseases

Retrieved on: 
Friday, November 10, 2023
Brain, Therapy, Computational biology, Communication, Validation, GPCR, Pharmaceutical industry

This is the first scientific milestone stemming from the strategic drug discovery collaboration between the two companies announced in 2022.

Key Points: 
  • This is the first scientific milestone stemming from the strategic drug discovery collaboration between the two companies announced in 2022.
  • The collaboration aims to leverage Sosei Heptares’ GPCR Diversified Compound Library and GPCR expertise and the innovative Kallyope Klarity™ platform, which combines single-cell sequencing, circuit mapping, computational biology and enteroid phenotypic screening.
  • The collaborating teams at Sosei Heptares and Kallyope intend to progress the nominated target into a fully supported structure-based drug discovery program as well as continuing to identify additional gastrointestinal targets for future programs.
  • It is exciting to see tangible outputs from our Target Identification and Validation strategy across our portfolio of collaborations with innovative companies, like Kallyope.